Shaping the future of LAAC therapy
Built on the proven performance of the world’s most studied LAAC device, the WATCHMAN FLX™ Left Atrial Appendage Closure Device1, the WATCHMAN FLX Pro Device features HEMOCOAT™ Technology to help promote faster, more complete endothelialization.2
Transforming AFib care for more patients
Breakthrough studies like the OPTION Clinical Trial and the SIMPLAAFY trial—inspired by early HEMOCOAT technology—are shaping a new era in LAAC and atrial fibrillation (AFib) care. These studies drive transformative outcomes, explore innovative post-implant drug regimens, and improve patient outcomes.
WATCHMAN FLX Pro LAAC Device
The WATCHMAN FLX Pro Device is designed with three first-ever features: new HEMOCOAT Technology designed to improve the healing process, radiopaque markers for precise device placement, and a new 40mm size for larger appendages.
*Enhanced healing demonstrated in pre-clinical model with no anticoagulation
Proven in performance, optimized for healing.
The WATCHMAN FLX Pro builds on the most studied and implanted LAAC device in the world by taking the next step forward in features and benefits.
Coated for controlled healing
HEMOCOAT Technology, a durable, thromboresistant coating, is designed to reduce inflammation for faster, more complete endothelialization.2
Established
PVDF-HFP has a long history of safe use on permanently implanted, blood-contacting medical devices.3
Stable
A durable, thin coating encapsulates the device’s healing surface, maintaining pore size and the mechanical performance of the WATCHMAN FLX platform (<1µm).4
Proven
Demonstrates impressive performance in a challenging preclinical model.4
How HEMOCOAT technology works to heal
Testing in pre-clinical model has demonstrated faster, more controlled healing.2
Enhanced visibility for greater precision
Three new radiopaque markers help improve visual accuracy, for precise device positioning and anchoring.
Enhance deployment precision
57% increased visibility for more accurate device positioning5
Ensure device stability
Improved assessment of device anchoring when performing tug test
Enable confident release
Improved visualization of device orientation and alignment
Close with confidence
A new 40mm size to help treat larger appendages
Expanded size, same trusted performance
- Same performance
- Same compression range (10‑30%)
- Same depth requirement
*Devices not shown to scale
WATCHMAN FLX Pro Device: An overview of the implant procedure
This video provides a quick procedural overview of the WATCHMAN FLX Pro implant, focusing on key steps, best practices, and secure placement of the left atrial appendage closure.
Flexibility to choose an optimal drug regimen
With the approval of immediate dual antiplatelet therapy (DAPT) post-implant, the WATCHMAN FLX Pro Device offers flexibility to choose the best drug regimen for your patient. Clinical outcomes that support its safety and efficacy in preventing thrombosis and reducing stroke risk. Additionally, the WATCHMAN FLX Pro Device is the only LAAC device that does not require an overnight stay after the procedure.
As always, you should exercise clinical judgment based on individual patient characteristics in determining the most appropriate use of anti-thrombotic drugs for the post-implant medication regimen.
Post-implant DAPT drug regimen options
At TEE, if leak >5mm, patients remain on OAC + ASA until seal is documented (leak <5mm).
Learn about the OPTION randomized clinical trial
*Any P2Y12 inhibitor and aspirin
References
1. Kar, S., et al, Circulation, 2021
2. Saliba et al. JACC: Clinical Electrophysiology, May 2023. Bench testing or pre-clinical study results may not necessarily be indicative of clinical performance. N=12 in a pre-clinical canine study.
3. Wagner et al., Biomaterials Science: An Introduction to Materials in Medicine, 4th Edition, 2020.
4. Boston Scientific Data on file.
5. Bench study performed under CT by Boston Scientific. Data on file.